Clinicopathologic features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor mutational status

Indian Journal of Cancer

Volumn 50, Issue 2, 2013, Pages 94-101

  Bhatt, A D ^a   Pai, R ^a   Rebekah, G ^a   Nehru, G ^a   Dhananjayan, S ^a   Samuel, A ^a   Singh, A ^a   Joel, A ^a   Korula, A ^a   Chacko, Raju Titus ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Chemotherapy; epidermal growth factor receptor; lung; tyrosine kinase inhibitors

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONFERENCE PAPER; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; INDIA; LUNG NON SMALL CELL CANCER; MALE; MUTATIONAL ANALYSIS; PROGRESSION FREE SURVIVAL; ADOLESCENT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDIA; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84884306270     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.117016     Document Type: Conference Paper

References (37)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127: 2893-917.
2. Moore MA, Ariyaratne Y, Badar F, Bhurgri Y, Datta K, Mathew A, et al. Cancer epidemiology in South Asia-past, present and future. Asian Pac J Cancer Prev 2010;11(Suppl 2): 49-66.
3. Gajalakshmi CK, Ravichandran K, Shanta V. Tobacco-related cancers in Madras, India. Eur J Cancer Prev 1996;5: 63-8.
4. Jayalekshmy PA, Akiba S, Nair MK, Gangadharan P, Rajan B, Nair RK, et al. Bidi smoking and lung cancer incidence among males in Karunagappally cohort in Kerala, India. Int J Cancer 2008;123: 1390-7.
5. Koul PA, Kaul SK, Sheikh MM, Tasleem RA, Shah A. Lung cancer in the Kashmir valley. Lung India 2010;27: 131-7.
6. Yeole BB. Respiratory cancer population-based survival in Mumbai, India. Asian Pac J Cancer Prev 2005;6: 449-54.
7. Gadgeel SM, Ramalingam S, Cummings G, Kraut MJ, Wozniak AJ, Gaspar LE, et al. Lung cancer in patients <50 years of age: The experience of an academic multidisciplinary program. Chest 1999;115: 1232-6.
8. Itaya T, Yamaoto N, Ando M, Ebisawa M, Nakamura Y, Murakami H, et al. Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci 2007;98: 226-30.
9. Gadgeel SM, Ali S, Philip PA, Ahmed F, Wozniak A, Sarkar FH. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer 2007;110: 2775-84.
10. Huang CL, Yokomise H, Fukushima M, Kinoshita M. Tailor-made chemotherapy for non-small cell lung cancer patients. Future Oncol 2006;2: 289-99.
11. Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-Rearranged non-small cell lung cancer: A success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012;17: 1351-75.
12. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305: 1163-7.
13. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65: 226-35.
14. Gonzalez MR, Martinez NE, Eugenieva E, Fernandez Morejon FJ, Farre J, Brugarolas A. A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib. Clin Transl Oncol 2008;10: 442-4.
15. Ku GY, Haaland BA, de Lima LG, Jr. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials. Lung Cancer 2011;74: 469-73.
16. Brown T, Boland A, Bagust A, Oyee J, Hockenhull J, Dundar Y, et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 2010;14(Suppl 2): 71-9.
17. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26: 2442-9.
18. Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, Nargund A, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 2011;73: 316-9.
19. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
20. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350: 2129-39.
21. Dey A, Biswas D, Saha SK, Kundu S, Kundu S, Sengupta A. Comparison study of clinicoradiological profile of primary lung cancer cases: An Eastern India experience. Indian J Cancer 2012;49: 89-95.
22. Krishnamurthy A, Vijayalakshmi R, Gadigi V, Ranganathan R, Sagar TG. The relevance of "Nonsmoking-associated lung cancer" in India: A single-centre experience. Indian J Cancer 2012;49: 82-8.
23. Noronha V, Dikshit R, Raut N, Joshi A, Pramesh CS, George K, et al. Epidemiology of lung cancer in India: Focus on the differences between non-smokers and smokers: A single-centre experience. Indian J Cancer 2012;49: 74-81.
24. Rawat J, Sindhwani G, Gaur D, Dua R, Saini S. Clinico-pathological profile of lung cancer in Uttarakhand. Lung India 2009;26: 74-6.
25. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: Male: Female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117: 294-9.
26. Brandao GD, Brega EF, Spatz A. The role of molecular pathology in non-small-cell lung carcinoma-now and in the future. Curr Oncol 2012;19(Suppl 1):S24-32.
27. Lung cancer biomarker guidelines: Draft recommendations of the College of American pathologists. CAP/IASLC/AMP Expert Panel-College of American Pathologists, International Association for the Study of Lung Cancer, Association of Molecular Pathology: 2011.
28. Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: Correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012;7: 323-30.
29. Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26: 2745-53.
30. Cohen V, Agulnik JS, Ang C, Kasymjanova G, Batist G, Small D, et al. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: Impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors. Cancer 2010;116: 4309-17.
31. Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009;15: 4493-8.
32. Liu S, Wang D, Chen B, Wang Y, Zhao W, Wu J. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer 2011;73: 203-10.
33. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361: 947-57.
34. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): A double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13: 247-55.
35. Dickson R, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: A NICE single technology appraisal. Pharmacoeconomics 2011;29: 1051-62.
36. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009;27: 5080-7.
37. Coudert B, Ciuleanu T, Park K, Wu YL, Giaccone G, Brugger W, et al. Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol 2012;23: 388-94.